Q-omics provides the consensus-scored MOCS1 profile across patient tissues and cancer cell-line models. MOCS1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MOCS1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, MOCS1 protein abundance shows 21,739 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, COAD, and GBM as cancer lineages where MOCS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MOCS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MOCS1 survival associations across molecular data types. MOCS1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MOCS1 RNA expression–survival associations across cancer types. High MOCS1 expression shows unfavorable associations in STAD, COAD and CESC, but favorable associations in KIRC, LUAD and ACC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for MOCS1 RNA expression.
This table summarizes MOCS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MOCS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MOCS1 shows lower tumor expression in COAD, THCA, LUAD, KIRP, LUSC and BRCA. The COAD box plot shows higher MOCS1 RNA expression in normal versus tumor tissue (log2 FC = −1.613, t-test p < 0.001).
This table shows molecular features associated with MOCS1 in patient tissues and cancer cell lines. In patient samples, MOCS1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MOCS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
